Physician profile
Parol P Pitroda
NPI 1225064686
$2,594.51
in general payments reported to CMS, 2019-2025
24 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $530 · 2021: $82.49 · 2022: $184 · 2023: $176 · 2024: $183 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $788.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $608.46 | 2019-2020 | |
| Tactile Systems Technology INC | $309.91 | 2019-2025 | Nimbl, Flexitouch Plus |
| Avanir Pharmaceuticals, INC. | $251.69 | 2019-2022 | |
| Medtronic, INC. | $233.90 | 2022-2024 | Venaseal |
| Kci USA, INC. | $199.26 | 2019 | |
| Smith+Nephew, INC. | $191.92 | 2019-2020 | |
| Organogenesis INC. | $127.44 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $125.63 | 2023-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Novo Nordisk INC | $90.11 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $71.96 | 2025 | Zepbound, Mounjaro, Kisunla |
| Sumitomo Pharma America, INC. | $50.34 | 2023 | Gemtesa |
| Boston Scientific Corporation | $29.08 | 2020 | |
| Watermark Medical, INC. | $26.86 | 2022 | |
| Kerecis Limited | $22.88 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $21.42 | 2025 | Rexulti |
| Exact Sciences Corporation | $18.77 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $18.68 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $17.10 | 2021 | |
| Philips North America LLC | $16.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2021 | |
| Medtronic Vascular, INC. | $16.12 | 2020 | |
| Ascensia Diabetes Care US INC. | $15.72 | 2024 | |
| Pfizer INC. | $14.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parol Pitroda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.